Despite that, a triple combination of atezolizumab, an anti-PD-L1 monoclonal antibody, with vemurafenib plus cobimetinib was granted FDA approval in 2020 as a first-line therapy option for patients with advanced BRAFV600E-mutant melanoma [124]. The gene discussed is CD274; the disease is melanoma.